

CITATION REPORT

List of articles citing

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial

DOI: 10.1161/circulationaha.111.055970
Circulation, 2012, 125, 669-76.

Source: <https://exaly.com/paper-pdf/52386359/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
338	HERBERT DINGLE [1972]: Science at the Crossroads. London: Martin Brian and O'Keeffe. Pp. 256. £3.00. 1975 , 26, 358-362		2
337	Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. 2012 , 98, 1404-6		19
336	Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. 2012 , 23, 380-90		3
335	Treatment of venous thromboembolism with dabigatran. 2012 , 18, 410-5		12
334	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. 2012 , 27, 331-9		9
333	Advances in the management of atrial fibrillation. 2012 , 12, 544-52		
332	Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. 2012 , 19, 4688-98		5
331	Antikoagulation bei Vorhofflimmern: Neue Substanzen - fflwen (nicht)?. 2012 , 1, 192-198		
330	[Secondary prevention of ischemic stroke--Part 1]. 2012 , 80, 654-68; quiz 668-70		0
329	Nonhemostatic adverse effects of anticoagulants and antiplatelet agents. 2012 , 38, 884-92		8
328	A review of oral anticoagulants in patients with atrial fibrillation. 2012 , 124, 7-16		68
327	Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. 2012 , 13, 1087-90		1
326	The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. 2012 , 343, 253-7		68
325	New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. 2012 , 2012, 502378		
324	Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. <i>Circulation</i> , 2012 , 125, 1577-83	16.7	16
323	Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. 2012 , 43, 3442-53		211
322	Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. 2012 , 43, 1179-85		7

321	Mehr Herzinfarkte, aber Gesamtnutzen bleibt erhalten. 2012 , 12, 61-62	
320	Current world literature. 2012 , 18, 835-40	
319	Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations. 2012 , 7, 166-74	2
318	Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. 2012 , 2,	51
317	Bibliography--Editors' selection of current world literature. 2012 , 23, 359-65	
316	Bibliography-editors' selection of current world literature. 2012 , 23, 303-5	
315	Dabigatran etexilate for the prevention of stroke in patients with nonvalvular atrial fibrillation. 2012 , 9, 629-637	
314	New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. 2012 , 13, 2649-61	8
313	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. 2012 , 10, 1979-87	24
312	Dabigatran for stroke prevention in atrial fibrillation. 2012 , 32, 216-20	0
311	Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?. 2012 , 79, 705-20	1
310	Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants. 2012 , 26, 331-8	7
309	A comparison of bleeding complications post-ablation between warfarin and dabigatran. 2012 , 35, 29-33	47
308	Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. 2012 , 8, 1483-93	1
307	[Prevention of thromboembolism in atrial fibrillation]. 2012 , 31 Suppl 1, 17-26	1
306	Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants. 2012 , 10, 433-9	6
305	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. 2012 , 14, 1385-413	1019
304	Erhöht der neue direkte Thrombin-Inhibitor das Herzinfarktrisiko?. 2012 , 14, 14-16	

303	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. 2012 , 345, e7097	98
302	Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. 2012 , 5, 711-9	87
301	Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. 2012 , 28, 125-36	389
300	Most important outcomes research papers on anticoagulation for cardiovascular disease. 2012 , 5, e65-74	10
299	Anticoagulation therapy. Dabigatran and risk of myocardial infarction. 2012 , 9, 260-2	23
298	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. 2012 , 59, 1413-25	211
297	Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. 2012 , 172, 1537-45	52
296	Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. 2012 , 9, 1923-9	48
295	Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. 2012 , 157, 796-807	140
294	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. 2012 , 33, 2719-47	2638
293	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. 2012 , 107, 838-47	169
292	Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. <i>Thrombosis</i> , 2012 , 2012, 108983	10
291	Dabigatran in atrial fibrillation: New kid on the block. 2012 , 145, 83-87.e1	2
290	New oral anticoagulants: which one should my patient use?. 2012 , 2012, 536-540	30
289	Dabigatran for stroke prevention in atrial fibrillation. 2012 , 7, 427-430	3
288	Nuevos anticoagulantes orales en la prevención del ataque cerebrovascular. 2012 , 50, 239-248	
287	HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION. 2012 , 8, 819-825	
286	Direct thrombin inhibitors in cardiovascular disease. 2012 , 9, 402-14	24

285	Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. 2012 , 60, 738-46	241
284	Recent clinical trials in atrial fibrillation in hypertensive patients. 2012 , 14, 350-9	7
283	Apixaban: a new option for stroke prevention in atrial fibrillation?. 2012 , 13, 8-13	
282	Anticoagulant therapy for patients with ischaemic stroke. 2012 , 8, 319-28	25
281	[New anticoagulants for stroke prevention in atrial fibrillation]. 2012 , 37, 370-7	3
280	[Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice]. 2012 , 37, 384-92	1
279	Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. 2012 , 29, 491-507	22
278	New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. 2012 , 271, 554-65	24
277	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. 2012 , 87 Suppl 1, S100-7	4
276	New oral anticoagulants: a view from the laboratory. 2012 , 87 Suppl 1, S133-6	28
275	Novel oral anticoagulants in non-valvular atrial fibrillation. 2013 , 26, 115-29	25
274	New oral anticoagulants after acute coronary syndrome. 2013 , 26, 141-50	0
273	Novel oral anticoagulants for atrial fibrillation. 2013 , 15, 344	13
272	Kommentar: Fokus Update der Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des Vorhofflimmerns. 2013 , 7, 171-180	4
271	Stroke Prevention in Atrial Fibrillation. 2013 , 1, 98-104	
270	[Stroke prevention in atrial fibrillation : old and new anticoagulants]. 2013 , 38, 231-8	
269	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. 2013 , 67, 516-26	16
268	Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. 2013 , 112, 1973-9	69

267	Circulation Editors' Picks. <i>Circulation</i> , 2013 , 128,	16.7
266	Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. 2013 , 170, 215-20	44
265	Personalizing oral anticoagulant treatment in patients with atrial fibrillation. 2013 , 11, 959-73	10
264	Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices. 2013 , 29, 1165-72	13
263	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. 2013 , 36, 163-74	15
262	Anticoagulants, renal failure and atrial fibrillation. 2013 , 12, 1-3	8
261	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 2013 , 11, 1029-49	4
260	Oral anticoagulants to reduce the risk of stroke in atrial fibrillation: how should a clinician choose?. 2013 , 36, 663-70	3
259	Nieuwe orale anticoagulantia. 2013 , 56, 337-341	
258	New avenues for anticoagulation in atrial fibrillation. 2013 , 93, 68-77	20
257	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. 2013 , 35, 295-301	53
256	Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. 2013 , 168, 4678-84	39
255	Impact of atrial fibrillation on outcomes in heart failure. 2013 , 9, 437-49, viii	0
254	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. 2013 , 15, 625-51	622
253	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012: Actualizaci3n de las gu3as de la Sociedad Europea de Cardiolog3a (ESC) para el manejo de la fibrilaci3n auricular de 2010 Elaborada en colaboraci3n con la Asociaci3n Europea del Ritmo Cardiaco. 2013 , 66, 54.e1-54.e24	10
252	Nuevos anticoagulantes orales y su papel en la pr3ctica cl3nica. 2013 , 13, 33-41	1
251	Questions pratiques dans le traitement de la fibrillation atriale. 2013 , 5, 148-160	
250	[Improvements in oral anticoagulant therapy for atrial fibrillation]. 2013 , 141, 487-93	2

249	New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures. 2013 , 8, 115-22	12
248	New anticoagulants in atrial fibrillation management. 2013 , 131 Suppl 1, S63-6	1
247	Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. 2013 , 368, 709-18	693
246	Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. 2013 , 61, 2264-73	342
245	Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses. 2013 , 36, 155-62	1
244	Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. 2013 , 143, 1106-1116	23
243	The new oral anticoagulants in clinical practice. 2013 , 88, 495-511	79
242	Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation : Update on Prevention of Stroke in Patients with AF. 2013 , 15, 583-92	
241	Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. 2013 , 29, S60-70	9
240	Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. 2013 , 11, 615-26	23
239	Antithrombotic Therapy in Atrial Fibrillation. 2013 , 2, e1-e31	
238	Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. 2013 , 15, 1526-32	17
237	Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation. 2013 , 41, 49-60	
236	Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants. 2013 , 36, 312-22	4
235	Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. 2013 , 13, 29-42	6
234	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. 2013 , 41, 37-48	1
233	Thrombosis in nephrotic syndrome. 2013 , 39, 469-76	54
232	Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents. 2013 , 13, 379-84	4

231	Relevance of stroke subtype in vascular risk prediction. 2013 , 81, 575-80	22
230	Current world literature. 2013 , 28, 80-4	
229	An unusual cause of unilateral pulmonary edema. 2013 , 158, 639-40	1
228	One-year risk for advanced colorectal neoplasia. 2013 , 158, 639	1
227	Circulation Editors' Picks. <i>Circulation</i> , 2013 , 127,	16.7
226	Circulation Editors' Picks. <i>Circulation</i> , 2013 , 128,	16.7
225	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. 2013 , 125, 34-44	10
224	Novel direct-acting anticoagulants for risk reduction in ACS. 2013 , 26, 358-66	2
223	Atrial fibrillation and stroke - reading list. 2013 , 1, 26-26	
222	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. 2013 , 11, 1619-29	12
221	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. 2013 , 11, 77-90	7
220	Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. 2013 , 11, 1461-71	2
219	Current approaches to anticoagulation for reducing risk of atrial fibrillation-related stroke. 2013 , 26, 204-13	2
218	Estimating overdiagnosis of lung cancer. 2013 , 158, 635	10
217	Comparative effectiveness of warfarin and new anticoagulants. 2013 , 158, 637-8	
216	Comparative effectiveness of warfarin and new anticoagulants. 2013 , 158, 636-7	
215	Comparative effectiveness of warfarin and new anticoagulants. 2013 , 158, 637	
214	Practical approaches to the treatment of atrial fibrillation: focus on stroke prevention using oral anticoagulant drugs. 2013 , 10, 317-332	

213	Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. 2013 , 144, 1839-1847	27
212	Estimating overdiagnosis of lung cancer--reply. 2013 , 158, 635-6	2
211	One-year risk for advanced colorectal neoplasia. 2013 , 158, 638-9	
210	Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. 2013 , 9, 599-615	30
209	Is there really misuse and abuse of dabigatran?. 2013 , 198, 358-9	3
208	Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. <i>Thrombosis</i> , 2013 , 2013, 640723	122
207	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. 2013 , 9, 341-52	13
206	ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES. 2013 , 9, 171-176	
205	Targeting factor Xa and thrombin: impact on coagulation and beyond. 2014 , 111, 625-33	88
204	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?. 2014 , 10, 507-22	14
203	Dabigatran and myocardial infarction: a foggy scenario. 2014 , 10, 45-8	
202	Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. 2014 , 36, 2015-2028.e2	30
201	Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial. 2014 , 45, 3076-9	12
200	Incomplete isolated cleft of the anterior mitral valve: first reported as triangular defect. 2014 , 35, 256	2
199	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?. 2014 , 42, 153-62	1
198	Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. 2014 , 39, 628-36	8
197	Antithrombotics in atrial fibrillation and coronary disease. 2014 , 12, 977-86	4
196	Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. 2014 , 37, 32-47	64

195	Anticoagulants oraux directs, fibrillation atriale et accidents vasculaires cérébraux. 2014 , 5, 269-276	
194	Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. 2014 , 12, 1054-65	45
193	Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. 2014 , 28, 575-85	18
192	Which drug should we use for stroke prevention in atrial fibrillation?. 2014 , 29, 293-300	6
191	Increased risk of myocardial infarction with dabigatran: fact or fiction?. 2014 , 15, 19-26	7
190	New oral anticoagulant agents - general features and outcomes in subsets of patients. 2014 , 111, 575-82	42
189	Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. 2014 , 3, e000515	73
188	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. 2014 , 111, 798-807	38
187	Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. 2014 , 2014, 901586	5
186	Protecting the brain and the heart: antithrombotic treatment in nonvalvular atrial fibrillation. 2014 , 65, 372-8	1
185	Direct oral anticoagulants in atrial fibrillation. 2014 , 51, 139-46	2
184	Papel de los nuevos anticoagulantes orales en la cardiopatía isquémica. 2014 , 49, 95-98	0
183	Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. 2014 , 127, 329-336.e4	56
182	The new era of anticoagulation. 2014 , 28, 503-14	4
181	Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. 2014 , 78, 707-17	32
180	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. 2014 , 35, 617-631	
179	Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. 2014 , 16, 293-8	30
178	Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants. 2014 , 35, 207-8	

177	Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. 2014 , 35, 250-6	103
176	Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 2014 , 45, 3754-832	921
175	Concerns over data in key dabigatran trial. 2014 , 349, g4747	17
174	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventionalists (EAPCI) and the European Association of Cardiothoracic Surgeons (EACTS). 2014 , 35, 3153-3170	413
173	Novel anticoagulants for stroke prevention in patients with atrial fibrillation. 2014 , 28, 247-62	4
172	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 2014 , 35, 233-41	67
171	Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. 2014 , 19, 190-204	10
170	¿Qué aportan los nuevos anticoagulantes en la prevención del tromboembolismo venoso y arterial?. 2014 , 31, 102-109	
169	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. 2014 , 111, 549-56	17
168	Anticoagulant Management of Heparin-Compromised Patients. 2014 , 60-65	
167	Response. 2015 , 147, e71-e72	
166	Dabigatran and myocardial infarction. 2015 , 147, e70-e71	6
165	Vorhofflimmern: orale Antikoagulation. 2015 , 15, 52-56	
164	Insights into direct anticoagulants. 2015 , 26, 492-8	1
163	Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation. 2015 , 9, 314	
162	Anticoagulation in Atrial Fibrillation - Current Concepts. <i>Arrhythmia and Electrophysiology Review</i> , 2015 , 4, 100-7	3-2 4
161	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. 2015 , 10, 1431-44	14
160	10 Venous Thromboembolism (DVT and PE): Diagnosis and Treatment. 2015 ,	

159	New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. 2015 , 11, 967-77	227
158	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. 2015 , 10, e0125164	9
157	New Oral Anticoagulants in Coronary Artery Disease. 2015 , 15, 101-5	5
156	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). 2015 , 2015, 798486	11
155	Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. 2015 , 5, 234-44	8
154	Evidencias actuales de los nuevos anticoagulantes orales en el tratamiento de la fibrilaci3n auricular no valvular: comparaci3n de subestudios. 2015 , 68, 185-189	5
153	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. 2015 , 278, 1-18	53
152	Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. 2015 , 1, 191-7	8
151	New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. 2015 , 196, 133-8	16
150	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. 2015 , 8, 383-92	42
149	Does myocardial infarction beget atrial fibrillation and atrial fibrillation beget myocardial infarction?. <i>Circulation</i> , 2015 , 131, 1824-6	16.7 17
148	Current evidence for new oral anticoagulants in the treatment of nonvalvular atrial fibrillation: comparison of substudies. 2015 , 68, 185-9	2
147	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants. 2015 , 47, 278-88	
146	New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?. 2015 , 10, 493-8	1
145	Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. 2015 , 113, 1193-202	20
144	Practical management of anticoagulation in patients with atrial fibrillation. 2015 , 65, 1340-1360	67
143	Dabigatran for the prevention and treatment of thromboembolic disorders. 2015 , 13, 529-40	6
142	[Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation]. 2015 , 140, 750-5	1

141	Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study. 2015 , 243, 192-7	21
140	The evolving role of dabigatran etexilate in clinical practice. 2015 , 16, 2053-72	
139	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. 2015 , 17, 1467-507	803
138	Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin. 2015 , 136, 658-62	8
137	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. 2015 , 170, 1151-60	73
136	National Trends in Ambulatory Oral Anticoagulant Use. 2015 , 128, 1300-5.e2	407
135	Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. 2015 , 40, 1-11	5
134	Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. 2015 , 39, 228-34	17
133	Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. 2015 , 39, 50-4	8
132	An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. 2015 , 24, 399-405	20
131	Uso de los anticoagulantes orales directos en la práctica clínica. 2016 , 64, 295	1
130	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. 2016 , 115, 622-31	21
129	Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. 2016 , 116, 1150-1158	6
128	Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. 2016 , 27, 185-9	1
127	Causes of Death in Anticoagulated Patients With Atrial Fibrillation. 2016 , 68, 2508-2521	142
126	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. 2016 , 8, 367ra168	27
125	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. 2016 , 115, 893-952	76
124	Surgeon's guide to anticoagulant and antiplatelet medications part two: antiplatelet agents and perioperative management of long-term anticoagulation. 2016 , 1, e000022	17

123	Usos de anticoagulantes directos en situaciones especiales. 2016 , 23, 89-94	
122	Clinical considerations on the posology of direct oral anticoagulants. 2016 , 216, 384-392	
121	Overview of direct oral anticoagulant therapy reversal. 2016 , 73, S5-S13	11
120	North American Thrombosis Forum, AF Action Initiative Consensus Document. 2016 , 129, S1-S29	19
119	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. 2016 , 32, 1170-1185	212
118	Novel oral anticoagulants in non-valvular atrial fibrillation: Pharmacological properties, clinical trials, guideline recommendations, new antidote drugs and real-world data. 2016 , 2, 167-173	3
117	Clinical considerations on the posology of direct oral anticoagulants. 2016 , 216, 384-392	
116	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. 2016 , 33, 555-564	58
115	Nuevos anticoagulantes orales ¿cuál elegir?. 2016 , 23, 95-99	
114	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. 2016 , 18, 74	60
113	A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. 2016 , 116, 241-50	6
112	Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. 2016 , 116, 754-63	66
111	NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. 2016 , 3, e000279	55
110	Individualized approaches to thromboprophylaxis in atrial fibrillation. 2016 , 173, 143-58	9
109	Enhanced TRAP-induced platelet aggregation with dabigatran - Clinical perspective. 2016 , 138, 61-62	
108	Secondary Prevention of Cardioembolic Stroke. 2016 , 1014-1029.e4	
107	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. 2016 , 16, 171-82	2
106	Safety of non-vitamin K antagonist oral anticoagulants - coronary risks. 2016 , 15, 731-40	5

105	Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. 2016 , 58, 483-94	20
104	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. 2016 , 14, 163-76	6
103	Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation. <i>Clinical Research in Cardiology</i> , 2016 , 105, 29-36	6.1 28
102	Heart Failure and Mortality in Patients With Nonvalvular Atrial Fibrillation Started on Novel Oral Anticoagulant Therapy: A Single-Center Experience. 2017 , 23, 454-459	3
101	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. 2017 , 23, 5-19	9
100	Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. 2017 , 83, 1532-1543	19
99	Dabigatran Etxilate: A Review in Nonvalvular Atrial Fibrillation. 2017 , 77, 331-344	12
98	Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?. 2017 , 282, 164-174	19
97	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. 2017 , 43, 365-379	62
96	Atrial Fibrillation and Percutaneous Coronary Intervention. 2017 ,	
95	Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. 2017 , 18, 467-477	6
94	Atrial fibrillation as a prognostic indicator of myocardial infarction and cardiovascular death: a systematic review and meta-analysis. 2017 , 7, 3360	4
93	Oral Anticoagulation Therapy. 2017 ,	1
92	Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. 2017 , 83, 1835-1843	9
91	Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. 2017 , 18, 67-77	5
90	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. 2017 , 11, CD011373	47
89	Drug therapy in anticoagulation: which drug for which patient?. 2017 , 17, 233-244	6
88	The use of direct oral anticoagulants in inherited thrombophilia. 2017 , 43, 24-30	49

87	Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants. 2017 , 136, 115-124	10
86	Appendix: Suggested Reading. 2017 , 699-741	
85	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. 2017 , 167, 845-854	33
84	Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran. 2017 , 9, e289-e293	8
83	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. 2018 , 16, 465-473	6
82	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. 2018 , 60, 514-523	7
81	The coagulation system in atherothrombosis: Implications for new therapeutic strategies. 2018 , 2, 188-198	25
80	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. 2018 , 50, 288-302	10
79	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. 2018 , 39, 1330-1393	1094
78	Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 2018 , 131, 1075-1085.e4	12
77	Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies. 2018 , 267, 1-7	21
76	Pleiotropic effects of the hemostatic system. 2018 , 16, 1464	10
75	Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. 2018 , 72, 17-26	34
74	Direct Oral Anticoagulants and Myocardial Infarction: The Dust Is Settling. 2018 , 72, 27-28	2
73	Response to comments of manuscript: Increased risk of myocardial infarction with dabigatran etexilate: Fact or fiction? A critical meta-analysis from integrating randomized controlled trials and real-world studies: Wine or spritzer?. 2018 , 270, 80	
72	Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. 2018 , 12, 247-262	7
71	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. 2018 , 20, F1-F74	17
70	THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION. 2018 , 34, 327-336	1

69	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. 2019 , 8, 176-185	13
68	Effects of Prevalent and Incident Chronic Kidney Disease on Cardiovascular Events in Patients with Atrial Fibrillation. 2019 , 8,	1
67	Adverse clinical events in Japanese atrial fibrillation patients with and without coronary artery disease-findings from the SAKURA AF Registry. 2019 , 35, 2053-2062	3
66	Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis. 2019 , 4, 2381468319866828	6
65	Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists. 2019 , 49, e13161	3
64	Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model. 2019 , 17, 538-550	5
63	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. 2019 , 18, 187-209	15
62	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. 2019 , 14, e0216831	12
61	Warfarin therapy in Chinese patients with atrial fibrillation treated with percutaneous coronary intervention: a 5 year follow-up retrospective cohort study. 2019 , 35, 1777-1783	2
60	Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study. 2019 , 119, 882-893	27
59	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. 2019 , 21, 1023-1030	4
58	Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. 2019 , 19, 37-47	5
57	The hidden side of oral thrombin inhibitors. 2019 , 274, 186-187	
56	Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents. 2019 , 28, 223-234	5
55	The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. 2019 , 8, 554-561	7
54	Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis. 2020 , 71, 27-37	8
53	Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis. 2020 , 25, 973-983	5
52	Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. 2020 , 37, 420-430	2

51	New oral anticoagulants for nonvalvular atrial fibrillation with stable coronary artery disease: A meta-analysis. 2020 , 43, 1393-1400			1
50	New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a meta-analysis. 2021 , 46, 352-358			
49	Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran. 2020 , 26, 1076029620972467			3
48	Fibrilaci3 auricular y cardiopat3 isqu3mica: m3 all3 de la prevenci3 del ictus. 2020 , 20, 11-20			
47	The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality. 2020 , 16, 301-306			
46	Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. 2020 , 76, 1111-1124			8
45	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease. 2020 , 61, 231-238			2
44	Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. 2021 , 121, 122-130			2
43	Plasma proteomic changes in patients with non-valvular atrial fibrillation starting rivaroxaban treatment: A pilot study. 2021 , 2, 100040			
42	Elderly patient with atrial fibrillation and coronary risks. 2021 , 51-57			
41	Structural Changes of Sodium Warfarin in Tablets Affecting the Dissolution Profiles and Potential Safety of Generic Substitution. 2021 , 13,			
40	Secondary Prevention of Cardioembolic Stroke. 2022 , 932-943.e4			
39	Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. 2015 , 13, 2012-20			102
38	Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions. <i>Thrombosis</i> , 2012 , 2012, 867121			4
37	Anticoagulation in Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2012 , 1, 12-16	3.2		2
36	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary. <i>Arrhythmia and Electrophysiology Review</i> , 2013 , 2, 115-9	3.2		2
35	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. <i>International Journal of General Medicine</i> , 2013 , 6, 167-80	2.3		13
34	Novel Direct Anticoagulants and Atherosclerosis. <i>Current Vascular Pharmacology</i> , 2019 , 17, 29-34	3.3		2

33	Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. <i>Current Cardiology Reviews</i> , 2014 , 10, 297-302	2.4	8
32	Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. <i>Current Cardiology Reviews</i> , 2017 , 13, 41-46	2.4	2
31	Selecting antithrombotic therapy for patients with atrial fibrillation. <i>Cleveland Clinic Journal of Medicine</i> , 2015 , 82, 49-63	2.8	3
30	Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. <i>Journal of Thoracic Disease</i> , 2015 , 7, 165-71	2.6	31
29	Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. <i>Cardiovascular Diagnosis and Therapy</i> , 2014 , 4, 314-23	2.6	9
28	The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations. <i>Journal of Atrial Fibrillation</i> , 2017 , 9, 1547	0.8	2
27	Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation. <i>Journal of Stroke</i> , 2013 , 15, 144-52	5.6	7
26	Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	0
25	Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4653	1.3	
24	Prevention of thromboembolic complications of atrial fibrillation: Current aspects and perspective. <i>Srce I Krvni Sudovi</i> , 2012 , 31, 68-76		0
23	[Novel agents for antithrombotic therapy in cardiology]. <i>Orvosi Hetilap</i> , 2012 , 153, 2016-20	0.8	
22	LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?. 2013 , 5, 1-8		
21	Rapport sur les anticoagulants oraux directs (AOD) (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO). <i>Bulletin De L'Académie Nationale De Médecine</i> , 2014 , 198, 1157-1195	0.1	
20	Thrombin inhibitors, direct. 2016 , 903-914		
19	Efficacy and Limitations of Warfarin and Novel Oral Anticoagulants with Atrial Fibrillation. <i>Contemporary Cardiology</i> , 2016 , 17-36	0.1	
18	New-Onset Atrial Fibrillation in a Stable Patient with Remote Percutaneous Coronary Intervention. 2017 , 141-152		
17	Atrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. 2017 , 121-140		
16	Patient with Concomitant Stable Coronary Artery Disease. 2017 , 69-73		

15	[Antithrombotic Therapy in Atrial Fibrillation and Chronic Ischemic Heart Disease]. <i>Kardiologiya</i> , 2019 , 59, 80-86	1.5	0
14	Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations. <i>Russian Journal of Cardiology</i> , 2019 , 133-141	1.3	1
13	[Risk of Coronary Events in Atrial Fibrillation]. <i>Kardiologiya</i> , 2020 , 60, 43-52	1.5	
12	Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 695-706	3.8	2
11	Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. <i>CADTH Technology Overviews</i> , 2013 , 3, e3202		12
10	Approach to the new oral anticoagulants in family practice: part 1: comparing the options. <i>Canadian Family Physician</i> , 2014 , 60, 989-95	0.9	11
9	More indications approved and safety news for dabigatran etexilate. <i>Mdica</i> , 2014 , 9, 405-7		
8	Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents. <i>Journal of Atrial Fibrillation</i> , 2013 , 6, 825	0.8	
7	Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2013 , 5, 732	0.8	
6	Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. <i>Ochsner Journal</i> , 2016 , 16, 531-541	1.5	4
5	MEDEX South Carolina: a progress report. <i>The Journal of the South Carolina Medical Association</i> , 1975 , 71, 337-8		
4	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
3	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. 2013 , 332-397		1
2	CHA2DS2-VASc Score, Mortality and Acute Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. 2022 ,		
1	Warfarin versus non-vitamin k antagonist oral anticoagulants: how the degree of coagulation differs during catheter ablation of atrial fibrillation. 2022 , 29, 13-20		0